Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics Limited reported a significant financial loss for the year ending June 30, 2025, with a net loss of $16,593,619, marking a 116.3% increase from the previous year. The company’s net assets also decreased substantially, reflecting challenges in its financial stability and potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited, formerly known as PharmAust Limited, operates in the pharmaceutical industry. The company focuses on developing therapeutic solutions, though specific primary products or services are not detailed in the release.
Average Trading Volume: 359,894
Technical Sentiment Signal: Hold
Current Market Cap: A$76.31M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.